From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
Cost-Effective and Scalable for Screening qPCR offers one of the most cost-effective solutions in early cancer diagnostics. While next-generation sequencing (NGS) can range from $300 to $3,000 per sample, qPCR tests typically cost between $50 and $200—making them far more accessible for large-scale screening and routine use. Its afford- ability extends beyond reagents to equipment, maintenance, data analysis, and labor. This cost advantage has enabled qPCR’s integration into national screening programs and low-resource settings. For example, in India, qPCR has been used to screen for HPV-driven cervical cancer since 2012, offering a faster, more scalable alternative to cytology. 2 Similarly, qPCR-based EGFR testing has been standard in many Chinese hospitals since
2016 due to its low cost and rapid turnaround, even in regional centers. 3 Scalability is another key strength. qPCR supports high-throughput formats (96- or 384-well plates), requires minimal input, and is easily automated— allowing labs to process hundreds or thousands of samples daily. During the COVID-19 pandemic, qPCR was used worldwide to test millions of samples, demonstrating its unmatched scalability under pressure. For early detection efforts and public health programs targeting high-incidence cancers like colorectal, cervical, and lung, qPCR provides a prac- tical balance of sensitivity, speed, and affordability, making it a powerful tool for both diagnosis and cancer prevention at scale.
Advances in qPCR Chemistry Driving Clinical Success While the core principles of qPCR have remained consistent since the 1990s, ongoing advances in qPCR chemistry have significantly enhanced its performance, robustness, and clinical applicability. These innovations have addressed early limitations around sensitivity, specificity, multiplexing, and sample compatibility, enabling qPCR to remain a frontline diagnostic tool even as molecular testing demands have grown more complex. Next-gener- ation DNA polymerases used in qPCR have been rationally designed or evolved through a combina- tion of site-directed mutagenesis, directed evolu- tion, and protein domain optimization to meet the demands of clinical diagnostics—particularly when
working with challenging sample types like FFPE tissue, blood, and plasma.
Key Areas of DNA Polymerase Enzyme Optimization for Modern Molecular Diagnostics
1. Inhibitor Resistance: ° Enzymes are engineered with mutations that reduce binding affinity to common PCR inhib- itors, such as heme (from blood), urea (from
24 | GENengnews.com
Powered by FlippingBook